Jim Cramer - Mad MoneyAquestive TherapeuticsAQSTDON'T BUYJan 16, 2026

Is hammered 43% the past month. What went wrong? Last week, the FDA sent them a letter citing big deficiencies in their Anaphylm drug application. This throws into doubt the approval of this drug. That said, don't sell AQST now, because there's a chance of approval. He's far less confident in AQST than before.